OGEN Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (19 Apr 2024 @ 11:02):

Stats
Today's Volume	11 050.00
Average Volume	98 864.00
Market Cap	5.26M
EPS	$0 ( 2024-04-17 )
Next earnings date	( $0 ) 2024-05-10
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.260
ATR14	$0.0140 (1.19%)

Insider Trading

Date	Person	Action	Amount	type
2023-12-31	Koski Robert C	Buy	0
2023-12-28	Redmond J Michael	Buy	75 000	Employee Option (Right to Buy)
2023-12-28	Redmond J Michael	Buy	0
2023-11-30	Telling Fred	Sell	3 500	Common Stock
2023-10-04	Gandolfo John P	Buy	5 102	Non-Employee Director Option (Right to Buy)

INSIDER POWER
46.47
Last 90 transactions
Buy: 9 608 650 \| Sell: 19 845 876

Volume Correlation

Long: -0.19 (neutral)

Short: 0.95 (very strong)

Signal:(58.433) Expect same movement, but be aware

Oragenics Inc Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Oragenics Inc Correlation - Currency/Commodity

-0.06
( neutral )

0.20
( neutral )

0.00
( neutral )

-0.09
( neutral )

0.67
( moderate )

-0.20
( neutral )

Oragenics Inc Financials

Annual	2023
Revenue:	$0
Gross Profit:	$-27 391.00 (0.00 %)
EPS:	$-9.18

Q4	2023
Revenue:	$0
Gross Profit:	$0 (0.00 %)
EPS:	$-4.14

Q3	2023
Revenue:	$7 466.00
Gross Profit:	$2 681.00 (35.91 %)
EPS:	$-0.850

Q2	2023
Revenue:	$13 163.00
Gross Profit:	$1 860.00 (14.13 %)
EPS:	$-1.510

Financial Reports:

No articles found.

Oragenics Inc

Oragenics, Inc. develops antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus; and Terra CoV-2, an intramuscular vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus. The company's product candidates also comprise LPT3-04, a weight loss candidate; and SMaRT Replacement Therapy, a topical treatment to prevent dental carries. It has a license agreement with Noachis Terra Inc. for licensing of certain specified patent rights and biological materials relating to the use of pre-fusion coronavirus spike proteins; and a collaboration agreement with Precigen, Inc. and ILH Holdings, Inc. for the development and commercialization of MU1140 and related homologs. The company was formerly known as Oragen, Inc. Oragenics, Inc. was incorporated in 1996 and is headquartered in Tampa, Florida.